ASN 2016 Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation: An Open-Label, Multicentre, Randomized Controlled Trial
High Impact Clinical Trial Session at the 2016 ASN
Christian Hugo, Michael Sean Wiesener, Mirian Opgenoorth, Oliver Thomusch. Dresden, Germany
In low-tacrolimus treated, immunologically low-risk renal transplant recipients, rapid steroid withdrawal is safe with no impact on survival or biopsy-proven acute rejection. Post-transplantation diabetes incidence is reduced from 39.2% to 23.9%(Basiliximab) or 22.7% (rATG) in rapid steroid withdrawal.
:
A Systematic Review on Steroid Withdrawal Between 3 and 6 Months After Kidney Transplantation
A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study
Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomized trial in paediatric renal transplantation
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Trial Results Conference Alert Source Type: research
More News: Allergy & Immunology | Cardiology | Cardiovascular | Clinical Trials | Conferences | Diabetes | Endocrinology | Heart | Kidney Transplant | Kidney Transplantation | Pediatrics | Prograf | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology